Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.
ECDC initiated a survey of EU/EEA countries to evaluate preparedness planning and risk mitigation initiatives implemented at the country level for people exposed to highly pathogenic avian influenza virus A(H5N1).
The aim of this survey was to review the expertise, capabilities and capacities for detection and characterisation of avian and other zoonotic influenza viruses in national influenza reference laboratories in the European Union/European Economic Area (EU/EEA), in members of the European Reference Laboratories for influenza (ERLINet), and in EU Enlargement policy countries.
In recent weeks, respiratory syncytial virus (RSV) circulation in the EU/EEA has intensified, with increasing transmission rates in all population groups and an earlier-than-usual start of the season. Several EU/EEA countries are experiencing high RSV circulation and the number of severe acute respiratory infections (SARI) due to RSV is increasing. At this time of the year RSV infections are not unusual, however this year there is more RSV activity and it began earlier than in pre-COVID-19 seasons.
This Threat Assessment Brief considers the risk of infection related to avian influenza A(H5N8) virus to the general population and the occupationally exposed.
A recently published study conducted between 2011 and 2018 in China, and based on surveillance data in pigs, identified an emerging genotype 4 (G4) reassortant Eurasian avian-like (EA) A(H1N1) swine influenza virus that contains internal genes from the human A(H1N1)pdm09 and North American triple-reassortant (TR) lineage-derived internal genes.